Thoroughbred Financial Services LLC bought a new position in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 8,475 shares of the company’s stock, valued at approximately $1,487,000.
A number of other institutional investors and hedge funds have also bought and sold shares of AZNCF. Mascoma Wealth Management LLC acquired a new position in AstraZeneca in the 4th quarter worth about $46,000. Elyxium Wealth LLC acquired a new position in AstraZeneca in the 4th quarter worth about $102,000. Redmont Wealth Advisors LLC acquired a new position in AstraZeneca in the 4th quarter worth about $122,000. Valley Wealth Managers Inc. acquired a new position in AstraZeneca in the 4th quarter worth about $144,000. Finally, Cary Street Partners Investment Advisory LLC acquired a new position in AstraZeneca in the 4th quarter worth about $412,000. Institutional investors and hedge funds own 40.87% of the company’s stock.
AstraZeneca Price Performance
Shares of AZNCF opened at $187.10 on Friday. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00. The business has a 50-day simple moving average of $187.10 and a two-hundred day simple moving average of $185.25.
About AstraZeneca
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Featured Stories
- Five stocks we like better than AstraZeneca
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
